Ethan Perlstein

Young Entrepreneurs Who Are Rewriting the Biopharma Business Model

Luke Timmerman, Elizabeth Iorns, Ethan Perlstein, D.A. Wallach, Alice Zhang

In response to stagnant R&D productivity despite rapid technological advancement, a coalition of entrepreneurs including Prolara's Ethan Perlstein, Science Exchange's Elizabeth, and Verge Genomics' Alice is deploying novel business models to accelerate drug discovery. These initiatives leverage CRISPR, data science, and patient-led capital to bypass traditional inefficiencies, aiming to fail early and validate molecular hypotheses faster than legacy pharmaceutical methods allow. The panel further advocates for structural reforms in academia and big pharma to integrate computational and biological expertise, ultimately seeking to transform biotech from a chemistry-based discipline into a software-driven engineering field.